Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011253 · ClinicalTrials.gov registry record · NA
Electronic Triggers: Microhematuria Trigger
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
NCT05011253: Completed NA study, sponsored by NYU Langone Health.
NCT05011253 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 2,000 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05011253, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.
Primary Outcome
Urology evaluation with cystoscopy and appropriate imaging
Interventions
- OTHER Electronic Trigger Microhematuria Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-06-06 |
| Phase | NA |
What the finished NCT05011253 record still lists
NCT05011253 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 1 intervention - of which Electronic Trigger Microhematuria Alert is the first listed.
NCT05011253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05011253 about?
NCT05011253 is a clinical study titled "Electronic Triggers: Microhematuria Trigger". The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.
What is the current status of trial NCT05011253?
This trial is currently completed. It is a NA study. The enrollment target is 2,000 participants. The study started on 2021-10-06. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT05011253?
The interventions under investigation include: Electronic Trigger Microhematuria Alert (OTHER).
Who is sponsoring clinical trial NCT05011253?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05011253's enrollment target sits among peer trials
2,000 52nd of 2000 higher than 1,947 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI